Sentences with phrase «tumor profiling in»

Published online by JCI Insight, it is the first report of «clinical implementation of tumor profiling in an enterprise - wide, unselected cancer patient population,» according to the authors.

Not exact matches

Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors.

Then they linked the drug sensitivity of the tumor cells to the profile of genes expressed in those cells.

In a recent attempt, oncologist Todd Golub of the Dana - Farber Cancer Institute in Boston, Massachusetts, and his colleagues collected gene expression profiles, taken from public databases, from 76 tumorIn a recent attempt, oncologist Todd Golub of the Dana - Farber Cancer Institute in Boston, Massachusetts, and his colleagues collected gene expression profiles, taken from public databases, from 76 tumorin Boston, Massachusetts, and his colleagues collected gene expression profiles, taken from public databases, from 76 tumors.

In a scenario where tumor profiling was already ordered, 79 % of patients stated they wanted to know all of the information obtained.

The 15 AACR scientists, who were already in Washington, D.C., to meet with the U.S. Food and Drug Administration on genetic testing for cancer patients, tossed around ideas including expanding NCI's tumor genome - sequencing efforts and getting the government to cover the costs of genomic tumor profiling.

Increasingly sophisticated tumor profiling technology has led to advancements in diagnosing and treating genetic diseases like cancer.

«While tumor profiling holds the promise of improved therapeutics through personalized medicine, it is important that both clinicians and patients discuss the possibilities of incidental findings prior to ordering the testing, as the findings can have serious implications for both the patient and their family members,» said Melinda Yushak, M.D., M.P.H., first author on the study and a medical oncology fellow in Yale School of Medicine.

A new effort by DOD, NCI, and the Department of Veterans Affairs will profile gene and protein expression in thousands of individuals» tumors.

Caris performed the molecular profiling on 48,733 solid tumor samples to assess the prevalence of homologous recombination deficiency in about 20 different types of solid tumors.

Researchers from BUSM and the University of Cyprus compared the markers on the surface of the cancer cells to gene expression profile of breast tumors deposited by researchers in international public databases and found that a molecule named IL13RA2 (IL13R alpha2) was abundant in metastatic or late - stage BLBC.

In 2011, she joined the institution's molecular diagnostics laboratory where she has been developing translational next generation sequencing assays and bioinformatics workflows for the Molecular Tumor Profiling Lab of the Yale Cancer Center.

This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular profile of individual tumors and the genetic background of patients.

«These findings raise the possibility that by determining the gene expression profile of a patient's tumor, physicians may be able to identify aggressive disease at the outset of diagnosis and start treatment earlier,» said Sungyong You, PhD, an instructor in the Cedars - Sinai Department of Surgery and the first author of the study.

The investigators also identified instances in which the genetic profiles of metastases were similar to those of only some cells in the primary tumor, suggesting that those cells were the source of the metastases, and other cases in which the genetic profiles of metastases from the same primary differed depending on their location.

A team led by principal investigator Donald M. O'Rourke, MD, an associate professor of Neurosurgery at Penn, and Marcela Maus, MD, PhD, showed that CART - EGFRvIII cells had an acceptable safety profile, crossed the blood - brain barrier, infiltrated the tumor, and prompted an immune response, resulting in reduction of the EGFRvIII tumor antigen in GBM cells.

The total environmental DNA of grape crown gall tumor disease is revealed in the genetic profile based on 52 tissue samples of crown gall tumor taken from 16 grapevine species.

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

Just over half of patients in the study who gave consent and had tumor profiling ordered by a physician actually received results, due to a variety of technical and logistical factors.

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors» mutations or being enrolled in clinical trials.

The study wasn't designed to measure whether tumor profiling made a difference in how patients fared, but «it nonetheless lays the groundwork for more systematic study of the impact of genomics on clinical practice and patient outcomes,» the report said.

Such targets have recently been discovered in cell lines derived from aggressive childhood tumors using phenotypic profiling and RNAi screening.

Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor.

Periostin (POSTN) was identified by microarray RNA profiling studies as a stromal factor involved in maintaining the normal stem cell niche and demonstrated to be secreted by stromal fibroblasts, but not by infiltrating tumor cells (Malanchi et al., 2012).

Individual profiles based on the analysis of each patient's tumor cells revealed clinically relevant information that could be used to prioritize the drugs most likely to be effective in these cases.

In these cases, drug exposure caused significant changes in tumor cells» gene expression profile but had no lasting physical effecIn these cases, drug exposure caused significant changes in tumor cells» gene expression profile but had no lasting physical effecin tumor cells» gene expression profile but had no lasting physical effect.

In recent years DNA - and RNA - based surveys of tumor genome and expression profiling have produced a plethora of leads on genes with clinical significance.

We subjected 474 mutant alleles curated from 5,338 tumors to pooled in vivo tumor formation assays and gene expression profiling.

The fact that she has found them to be differentially regulated in angiosarcoma tumors has led to the hypothesis that there are epigenetic regulators of these genes that have yet to be identified through the genomic profiling applied to these studies thus far.

In the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the genetic conditions predisposing to tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her genetic profile, in other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.&raquIn the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the genetic conditions predisposing to tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her genetic profile, in other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.&raquin other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.&raquin a selective way, killing only the deprogrammed cells.»

To determine the relevance of DDX3 in clinical cancers, the expression profile of DDX3 in various tumors was also examined.

Collaborations to access and profile immune cells in patient tumors are also underway to provide the relevant disease context for our current and future targets.

To further confirm the alteration of DDX3 expression in cancer specimens, the expression profiles of DDX3 were examined in normal - tumor paired HCC samples by immunohistochemical staining analysis using specific anti-DDX3 antibody.

Using an array of techniques, including RNA sequencing and targeted gene expression profiling, the researchers searched for links between gene activity and protein production in these tumors and the clinical outcomes of patients.

Zebrafish larva implanted with cancer patient's tumor (red) RITA FIOR / CHAMPALIMAUD CENTRE FOR THE UNKNOWNSee R. Fior et al., «Single - cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts,» PNAS, doi: 10.1073 / pnas.1618389114, 2017

The mRNA expression profile of DDX3 and p21waf1 / cip1 in 45 normal - tumor paired HCC samples was determined by quantitative real time - PCR (see Materials and Methods) and is shown as fold expression relative to its corresponding normal tissue.

Because DDX3 harbors growth - suppressive ability and transcriptional modulation activity of the p21waf1 / cip1 promoter, in this work we further examined the deregulated expression of DDX3 in tumors by a cancer profiling array and immunohistochemical staining analysis.

Whether identifying rare subclones missed by standard bulk sequencing, or identifying co-mutation patterns in subclones, Tapestri Single - Cell DNA Panels can be applied across a wide number of applications, including hematologic malignancies, solid tumor profiling, and genome editing programs.

Single - cell DNA solid tumor profiling enables high resolution of the genomic diversity in a variety of tumor types.

Our groundbreaking Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing on the genetic analysis of pediatric cancer patients including in children with malignant brain tumors, and determines whether targeted treatments may be available based upon their personalized tumor genomic sequencing profiles.

Expression profiling of microRNA and other short or long non-coding RNAs in human tumors has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment.

22) Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly - Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, DePinho RA, Kemp CJ, Varmus HE, Hanash SM (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.

Examples include the study of allelic variation in the human genome and the development of computational methods for the discovery of cancer - associated genes and diagnostic cancer markers using genomic profiles derived from different tumor types.

Only a small fraction of a tumor can be obtained in a diagnostic or pretreatment biopsy, and thus the region of withdrawal could have a direct impact on the acquired expression profile.

366/12: 15 Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2: ERG fusion positive versus negative tumors.

Title: Infiltrating immune cells in breast cancer subtypes Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.

Modeling mRNA expression heterogeneity in tumors through bimodal profiles is a novel powerful approach with the potential to uncover therapeutic targets that benefit subsets of cancer patients.

Dr. Tallaly asserted,» The sprouts are not only quantitatively different than mature broccoli in their concentrations of chemoprotectants [that protect against tumor formation], they are qualitatively different in their profiles.»

45 hours of continuing education including: Lyme Disease Consensus and Update, Testing and Treatment, Feline Nutrition, Separation Anxiety, Behavior Modification, Feline Renal Disease, Mammary Tumors, Fluid Therapy in Critically Ill Dogs & Cats, Periodontal Disease Management, Insulin Therapy in Dog & Cats, Feline Cardiomyopathy, Blood Chemistry Profiling and Trending, Dermatology updates, Feline Colitis, Feline Vomiting, Nutrient Support in Canine Heart Failure

While not diagnostic for SCC, the diagnostic work - up includes complete blood count and serum chemistry profile, lymph node assessment via cytology, and chest x-rays in order to confirm that the tumor SCC is confined to the mouth.